Lupin Limited has informed the Exchange regarding a press release dated February 26, 2026, titled "Lupin Ranks No. 1 Globally in Pharma; Tops All Sectors in India in S&P ESGAssessment 2025".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin Limited has announced that it has been ranked the top pharmaceutical company globally and the top company across all sectors in India in the S&P Global Corporate Sustainability Assessment (CSA) 2025, scoring 91 out of 100. The company is among the top 1% of companies worldwide assessed by S&P, out of more than 9,200 companies across 59 industries. Lupin has been included in the S&P Global Sustainability Yearbook 2026 for the third consecutive year, with only 848 companies making the cut. Ramesh Swaminathan, Lupin's Executive Director and Global CFO, said the recognition reinforces the company's long-term commitment to embedding ESG principles into its business strategy.
This is a non-financial ESG recognition and is unlikely to move the stock price directly. However, it strengthens Lupin's global brand reputation, may attract ESG-focused institutional investors, and supports its premium valuation narrative in the long term.